Basic Trial Information
Trial Description
     Summary
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

Trial Description

Summary

The purpose of this study is to assess whether six months of daily finasteride (PROSCAR), following an initial negative prostate biopsy, will improve the detection of prostate cancer on repeat biopsy.

144 subjects with an initial negative prostate biopsy will be randomized to receive either finasteride or placebo for 6 months. The subjects will undergo a second prostate biopsy following drug intervention. PSA (prostate specific antigen) measurements, testosterone levels, and quality of life questionnaires will also be assessed during the study. The two groups will then be compared.

Eligibility Criteria

Inclusion Criteria:

• Initial biopsy, performed at UHN, of at least 8 cores with no evidence of cancer (HGPIN or ASAP allowed)

• PSA < 20 ng/ml

• Able to swallow and retain oral medication

• Able to read and write (IPSS questionnaire is self-administered), understand instructions related to study procedures and to give written informed consent.

Exclusion Criteria:

• Glucocorticoids, except inhaled or topical, are not permitted within 3 months prior to visit one.

• Concurrent and previous use within the past 12 months of the following medications: Finasteride (PROSCAR, Propecia), Dutasteride (Avodart), Any other investigational 5 alpha-reductase inhibitors, Anabolic steroids, drugs with antiandrogenic properties.

• Participation in an investigational or marketed drug trial within the 30 days prior to the first dose of study drug or anytime during the study period.

• Abnormal liver function test (greater than 2 times the upper limit of normal) for alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase; or bilirubin > 1.5 times the upper limit of normal.

• Serum creatinine > 1.5 times the upper limit of normal.

• Any unstable serious co-existing medical conditions including but not limited to myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias, clinically evident congestive heart failure, or cerebrovascular accident within 6 months prior to screening visit; uncontrolled diabetes or peptic ulcer disease which is uncontrolled by medical management.

• History of any illness (including psychiatric) that, in the opinion of the investigator, might confound the results of the study or pose additional risk to the subject.

• Known hypersensitivity to any 5 alpha-reductase inhibitor or to any drug chemically related to finasteride.

Trial Contact Information

Trial Lead Organizations/Sponsors

Toronto Western Hospital

Antonio Finelli, MD MSc FRCSC

Principal Investigator

Keri L Durrant, BSc., PGCR, CCRP		Ph: 416-946-4501 Ext.3431
		Email: keri.durrant@uhn.on.ca

Canada
Ontario
	Toronto
	Princess Margaret Hospital

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00542243
Information obtained from ClinicalTrials.gov on November 20, 2012

Back to Top